OncoMatch/Clinical Trials/NCT05917158
A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma
Is NCT05917158 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies RC48-ADC and JS001 for carcinoma.
Treatment: RC48-ADC and JS001 — This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with JS001 in postoperative adjuvant therapy for HER2-positive upper tract urothelial carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (2~3+)
Pathological tissue immunohistochemistry HER2 2~3+
Disease stage
Required: Stage PT2-PT4 PN0-2 M0, PTANY N1-2 M0
Histologically confirmed TCC staged pT2-pT4 pN0-2 M0 or pTany N1-2 M0 (providing all grossly abnormal nodes are resected)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radical nephro-ureterectomy — postoperative
Post radical nephro-ureterectomy for upper tract tumour
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify